Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Freedom Finance and Binance Join Forces in Digital Assets 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
VANCOUVER, British Columbia and WARMINSTER, Pa., April 30, 2018 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 3, 2018 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss first quarter 2018 financial results and provide a corporate update.
To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 4169558.
About Arbutus
Arbutus Biopharma Corporation is a publicly traded (Nasdaq:ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care (SOC) and contribute to a curative combination regimen to improve patient outcomes and deliver a potential cure for HBV. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Tiffany Tolmie
Manager, Investor Relations
Phone: 604-419-3200
Email: [email protected]
Media
David Schull
Russo Partners
Phone: 858-717-2310
Email: [email protected]
